注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Adicet Bio Inc是一家临床阶段生物技术公司。该公司致力于发现和开发异基因γ-δT细胞治疗癌症。它正在开发一条现成的γ-δT细胞管道,用嵌合抗原受体(CAR)和T细胞受体样抗体(TCRL)进行工程设计,以增强选择性肿瘤靶向性,促进先天性和适应性抗肿瘤免疫反应,并提高患者持久活动的持续性。其主要候选产品ADI-001是一种表达CAR靶向CD20的异基因γ-δT细胞疗法,目前正在进行非霍奇金淋巴瘤治疗的I期研究。其管道还包括ADI-002,一种表达GPC3靶向CAR和细胞内在可溶性形式的白细胞介素-15的异基因γδCAR-T细胞疗法,用于治疗实体瘤。此外,该公司还从事血液系统恶性肿瘤和实体瘤候选产品的发现和临床前阶段活动。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Jeffrey Allan Chodakewitz | 69 | 2020 | Independent Director |
Steve Dubin | 70 | 2020 | Independent Director |
Chen Schor | 52 | 2020 | CEO, President & Director |
Aya Jakobovits | 68 | 2020 | Founder & Independent Director |
Alice Bertaina | - | 2021 | Member of Scientific Advisory Board |
Michael Glen Kauffman | 61 | 2021 | Independent Director |
Saul Priceman | - | 2021 | Member of Scientific Advisory Board |
Marco L. Davila | - | 2021 | Member of Scientific Advisory Board |
Carl L. Gordon | 59 | 2020 | Independent Chairman |
Andrew Sinclair | 52 | 2021 | Independent Director |
Constantine Mitsiades | - | 2021 | Member of Scientific Advisory Board |
Lloyd Klickstein | 67 | 2020 | Member of Scientific Advisory Board |
Michael Kalos | - | 2021 | Member of Scientific Advisory Board |
Katie Peng | - | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核